BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 24726056)

  • 21. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.
    Zhang M; Hutter G; Kahn SA; Azad TD; Gholamin S; Xu CY; Liu J; Achrol AS; Richard C; Sommerkamp P; Schoen MK; McCracken MN; Majeti R; Weissman I; Mitra SS; Cheshier SH
    PLoS One; 2016; 11(4):e0153550. PubMed ID: 27092773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
    Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
    Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 24. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models.
    Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R
    Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma.
    Goto H; Matsuda K; Srikoon P; Kariya R; Hattori S; Taura M; Katano H; Okada S
    Cancer Lett; 2013 May; 331(2):174-82. PubMed ID: 23321500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
    Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
    Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells.
    Guo Z; Liu Y; Zhou H; Zheng K; Wang D; Jia M; Xu P; Ma K; Cui C; Wang L
    Colloids Surf B Biointerfaces; 2019 Dec; 184():110546. PubMed ID: 31606701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
    Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.
    Chao MP; Tang C; Pachynski RK; Chin R; Majeti R; Weissman IL
    Blood; 2011 Nov; 118(18):4890-901. PubMed ID: 21828138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.
    Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.
    Goto H; Kariya R; Kudo E; Okuno Y; Ueda K; Katano H; Okada S
    Oncogene; 2017 Sep; 36(37):5252-5262. PubMed ID: 28481873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
    Dai L; Lin Z; Qiao J; Chen Y; Flemington EK; Qin Z
    Oncogene; 2017 Aug; 36(35):5068-5074. PubMed ID: 28459467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting CD47 Inhibits Tumor Development and Increases Phagocytosis in Oral Squamous Cell Carcinoma.
    Ye XJ; Yang JG; Tan YQ; Chen XJ; Zhou G
    Anticancer Agents Med Chem; 2021; 21(6):766-774. PubMed ID: 32748759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
    Shigemi Z; Furukawa Y; Hosokawa K; Minami S; Matsuhiro J; Nakata S; Watanabe T; Kagawa H; Nakagawa K; Takeda H; Fujimuro M
    Int J Oncol; 2016 Jan; 48(1):293-304. PubMed ID: 26647777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
    Foster WR; Bischin A; Dorer R; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):311-21. PubMed ID: 27234438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.